CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 302 enrolled
Drug / intervention
Naltrexone +4 moredrug
Likely dose
Naltrexone 100 mg/day, up to 8 weeks during Phase 1, 16 weeks in Phase 2AI-extracted
Key inclusion· 8
  • Age ≥18 years
  • DSM-IV diagnosis of alcohol dependence confirmed by MINI interview
  • Drank alcohol within 30 days of randomization
  • Minimum 48 standard drinks (avg. 12/week) in a consecutive 30-day period during the 90 days prior to intake
Key exclusion· 9
  • Opiate abuse or dependence in past 12 months, or evidence of opiate use in month prior to treatment (prescription opioids allowed only if discontinued by randomization)
  • Current or recent dependence, abuse, or partial remission on substances other than alcohol (except nicotine and marijuana); positive urine drug screen (except THC) at initial visit or repeat testing
  • Lifetime DSM-IV diagnosis of schizophrenia or any psychotic disorder
  • Current DSM-IV diagnosis of post-traumatic stress disorder (PTSD) or bipolar disorder, or other disorders interfering with study participation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00115037
NCT00115037Phase 4Completed

Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism

University of Pennsylvania·interventional·Posted Jun 21, 2005·Updated Sep 18, 2019

In Brief

A Phase 4 clinical trial evaluating Naltrexone, placebo, and 3 other interventions for Alcoholism. Completed, enrolled 302 participants across 1 site.

Detailed Summary

This is a study involving treatment for alcohol dependence (alcoholism). The study will combine motivational enhancement therapy and cognitive behavioral therapy (combined behavioral intervention, or CBI) and tests the benefits of continued/discontinued treatment with naltrexone in a randomized placebo-controlled trial. CBI may have advantages in motivating patients to greater medication adherence and may address psychosocial factors that may limit the effects of naltrexone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 21, 2005
Enrollment StartSep 1, 2003
Primary CompletionApr 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 21.0 years ago

Interventions

Naltrexonedrug

100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.

placebodrug

placebo comparer for 16 weeks in phase 2.

Medication Management (MM)behavioral

Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.

Combined Behavioral Intervention (CBI)behavioral

45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.

Telephone Counselingbehavioral

Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.